AtriCure (ATRC) Q4 2025 earnings review
Profitability Inflection Overshadowed by Hybrid Therapy Decline
AtriCure achieved a major milestone in Q4, delivering its first GAAP Net Income ($1.8M) compared to a $15.6M loss a year ago. Operational leverage is kicking in, with Adjusted EBITDA surging 57% YoY to $19.9M. However, top-line growth (13.1%) is bifurcated: while Pain Management (+27%) and Open Ablation (+17%) are accelerating, the U.S. Minimally Invasive (MIS) segment collapsed 26% due to competitive pressure from Pulsed Field Ablation (PFA). FY26 guidance suggests stable mid-teens growth and continued margin expansion.
🐂 Bull Case
The transition from a $15.6M GAAP loss in 24Q4 to a $1.8M profit in 25Q4 proves the business model scales. FY25 Adjusted EBITDA nearly doubled to $61.8M, and FY26 guidance ($80-82M) implies further margin expansion.
The Pain Management franchise is accelerating, growing 27% in the U.S. in Q4. New products like cryoSPHERE MAX and the upcoming cryoXT for amputations provide a long runway for high-margin growth.
🐻 Bear Case
U.S. Minimally Invasive Ablation revenue dropped 26% YoY ($10.5M to $7.7M). The rapid adoption of PFA catheters by electrophysiologists is cannibalizing AtriCure's hybrid therapy volumes, creating a persistent drag on total growth.
With the MIS business shrinking, AtriCure is increasingly dependent on open-heart procedures (CABG/Valve concomitant). While EnCompass is performing well, any slowdown in cardiac surgery volumes would severely impact the growth narrative.
⚖️ Verdict: 🟢
Bullish. The successful pivot to GAAP profitability and strong cash generation outweighs the weakness in the shrinking MIS segment. The core Open Ablation and Pain Management franchises are growing fast enough (>15%) to absorb the PFA headwinds.
Key Themes
Minimally Invasive Segment Deterioration
The impact of Pulsed Field Ablation (PFA) on AtriCure's U.S. MIS business is severe. Revenue fell from $10.5M in 24Q4 to $7.7M in 25Q4 (-26%). This segment has turned from a growth driver into a significant drag. While management frames this as a temporary disruption until PFA non-responders emerge, the data shows a deepening contraction.
Pain Management Acceleration
Accelerating. The franchise grew 27.3% YoY in the U.S. to $22.6M. The adoption of cryoSPHERE MAX (faster ablation times) is driving utilization. This segment is becoming a major pillar of the company, now nearly 3x the size of the struggling MIS business.
Open Ablation Strength
Stable/Strong. U.S. Open Ablation revenue grew 16.7% YoY to $38.5M. The EnCompass clamp remains a key driver, allowing surgeons to perform ablations faster and more easily during concomitant procedures. This durability suggests the core cardiac surgery market is insulated from PFA threats.
Profitability Inflection Point
Accelerating. Gross margin expanded 45 bps to 75.0%. More importantly, operating leverage was substantial: Revenue grew $16.2M YoY while Operating Income swung from a $14.5M loss to a $2.5M profit. This confirms the business can self-fund future growth initiatives like the LeAAPS trial.
International Growth
Stable. International revenue grew 15.3% reported (9.9% constant currency). While positive, the divergence between reported and constant currency suggests FX tailwinds aided the quarter. Growth was broad-based across key markets.
Other KPIs
Steady growth of 12.8% YoY. While solid, this is a deceleration compared to the ~20% growth rates seen in prior quarters (e.g., Q3 was +21.5%). Driven by AtriClip FLEX-Mini adoption.
Stable. Improved 45 basis points YoY from 74.55% in 24Q4. FY25 gross margin also landed at 75.0%, up 29 bps. Management attributes this to favorable product mix (higher margin Pain Mgmt and Open Ablation products).
Strong. Cash and equivalents increased by ~$45M compared to year-end 2024 ($122.7M), driven by positive cash generation in H2 2025.
Guidance
Stable. The midpoint ($605M) implies 13.2% YoY growth, consistent with the 13.1% growth delivered in Q4 25. This suggests management does not expect the MIS drag to worsen significantly, nor do they expect a massive re-acceleration.
Accelerating. Midpoint implies ~31% growth YoY from FY25's $61.8M. The implied margin expansion continues, showcasing the scalability of the model even with ongoing clinical trial investments.
Accelerating. A clear shift to sustained profitability compared to the Adjusted Loss per share of $0.11 in FY25.
Key Questions
U.S. MIS Bottom Formation
U.S. Minimally Invasive revenue fell 26% this quarter. At what specific revenue run-rate do you model this segment stabilizing, and have you seen any evidence of the 'PFA non-responder' tailwind yet?
Appendage Management Deceleration
U.S. Appendage Management growth slowed to ~13% in Q4 from >20% in Q3. Was this driven by seasonality, market saturation in open procedures, or competitive pressures?
LeAAPS Trial Spend
With LeAAPS enrollment complete, how should we model the R&D expense cadence for FY26? Will the savings be reinvested into the BoxX-NoAF trial immediately?